What is the optimal anticoagulation level with argatroban during percutaneous coronary intervention?

Blood Coagulation and Fibrinolysis

Volumn 19, Issue 5, 2008, Pages 401-404

  Cruz Gonzalez, Ignacio ^a   Sanchez Ledesma, Maria ^a   Osakabe, Masanori ^b   Watanabe, Hikari ^b   Baron, Suzanne J ^a   Healy, Josephine L ^a   Yeh, Robert W ^a   Jang, Ik Kyung ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Activated clotting time levels; Argatroban; Direct thrombin inhibitor; Heparin induced thrombocytopenia; Percutaneous coronary intervention

Indexed keywords

ARGATROBAN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN;

ACUTE CORONARY SYNDROME; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING TIME; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ST SEGMENT ELEVATION; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; FEMALE; HEART DISEASES; HEMORRHAGE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PIPECOLIC ACIDS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; WHOLE BLOOD COAGULATION TIME;

EID: 63849185591     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328304e00d     Document Type: Article

References (16)

1. Jang IK, Hursting MJ. When heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation 2005; 111:2671-2683.
2. Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin. Thromb Haemost 1994; 72:381-386.
3. Lewis BE, Matthai WH Jr, Cohen M, Moses JW, Hursting MJ, Leya F. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002; 57:177-184.
4. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36:959-969.
5. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11:1-11.
6. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96:1703-1708.
7. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163:2518-2524.
8. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101:502-507.
9. Brieger DB, Mak KH, Kottke-Marchant K, Topol EJ. Heparin-induced thrombocytopenia. J Am Coll Cardiol 1998; 31:1449-1459.
10. Greinacher A. Treatment of heparin-induced thrombocytopenia. Thromb Haemost 1999; 82:457-467.
11. Yeh RW, Jang IK. Argatroban: update.Am Heart J 2006; 151:1131-1138.
12. Dang CH, Durkalski VL, Nappi JM. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy 2006; 26:461-468.
13. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114 (5 Suppl):489S-510S.
14. Jang IK, Lewis BE, Matthai WH Jr, Kleiman NS. Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot study. J Thromb Thrombolysis 2004; 18:31-37.
15. Cruz-Gonzalez I, Sanchez-Ledesma M, Baron S, Healy JL, Watanabe H, Osakabe M, et al. Efficacy and safety of Argatroban with or without glycoprotien IIb/IIIa inhibitor in patients with heparin induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary syndrome. J Thromb Thrombolysis 2008; 25:214-218.
16. Bahit MC, Cannon CP, Antman EM, et al. Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry. Am Heart J 2003; 145:109.